0000315066-16-005680.txt : 20160318 0000315066-16-005680.hdr.sgml : 20160318 20160318163504 ACCESSION NUMBER: 0000315066-16-005680 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160317 FILED AS OF DATE: 20160318 DATE AS OF CHANGE: 20160318 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REGENXBIO Inc. CENTRAL INDEX KEY: 0001590877 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9712 MEDICAL CENTER DRIVE STREET 2: SUITE 100 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 240-552-8181 MAIL ADDRESS: STREET 1: 9712 MEDICAL CENTER DRIVE STREET 2: SUITE 100 CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: REGENXBIO, Inc. DATE OF NAME CHANGE: 20150116 FORMER COMPANY: FORMER CONFORMED NAME: ReGenX Biosciences, LLC DATE OF NAME CHANGE: 20131101 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: FMR LLC CENTRAL INDEX KEY: 0000315066 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37553 FILM NUMBER: 161516490 BUSINESS ADDRESS: STREET 1: 245 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6175706339 MAIL ADDRESS: STREET 1: 245 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02210 FORMER NAME: FORMER CONFORMED NAME: FMR CORP DATE OF NAME CHANGE: 19920717 4 1 primary_doc.xml PRIMARY DOCUMENT X0306 4 2016-03-17 0 0001590877 REGENXBIO Inc. RGNX 0000315066 FMR LLC 245 SUMMER STREET BOSTON MA 02210 0 0 1 1 See Remark 1 Common Stock 2016-03-17 4 J 0 254965 0 D 830851 I See Footnote 1 F-Prime Capital Partners Healthcare Fund III LP made a pro-rata distribution to its partners, without payment of consideration, of 720,085 shares of REGENXBIO Inc. previously reported by FMR LLC. F-Prime Capital Partners Healthcare Fund III LP distributed 464,508 shares to Impresa Fund III Limited Partnership, 5,429 shares to F-Prime Capital Partners Healthcare Advisors Fund III LP (FPCPHA) and 250,148 shares to a recipient whose shares are not subject to reporting by the undersigned (an Other Recipient). FPCPHA made a pro-rata distribution to its partners, without payment of consideration, of 612 shares to F-Prime Inc, a wholly-owned subsidiary of FMR LLC, and 4,817 shares to Other Recipients. Remark 1: Abigail P. Johnson is a Director, the Vice Chairman, the Chief Executive Officer and the President of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The general partner of F-Prime Capital Partners Healthcare Fund III LP(f/k/a Beacon Bioventures Fund III Limited Partnership) is F-Prime Capital Partners Healthcare Advisors Fund III LP (f/k/a Beacon Bioventures Advisors Fund III Limited Partnership). F-Prime Capital Partners Healthcare Advisors Fund III LP is solely managed by Impresa Management LLC, its general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the family of Edward C. Johnson 3d. Remark 3: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Marc R. Bryant, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson 2016-03-18